Data Dictionary RNC - Luxembourg: Difference between revisions

From Beacon
No edit summary
No edit summary
 
(5 intermediate revisions by 3 users not shown)
Line 1: Line 1:
<span style="display:none">forresearchers</span>
<span style="display:none">luxembourgcountry</span>
Go back to [[Database: National Register of Cancer (RNC) (Luxembourg)]] page
Go back to [[Database: National Register of Cancer (RNC) (Luxembourg)]] page


Source: [https://www.rnc.lu/Portals/5/Documents/aspects_legaux/RNC_Manuel%20qualité_version%20validée_1.4_2014%2007%2003_LIH.pdf Click here to learn more]
Source: [https://www.rnc.lu/Portals/5/Documents/RGD_RNC.pdf Click here to learn more]


====Information provided by hospital cancer registries (RHC)====
====Information provided by hospital cancer registries (RHC)====
Line 42: Line 44:
'''Table 3''': Clinical description of the disease and staging.
'''Table 3''': Clinical description of the disease and staging.
{| class="wikitable"
{| class="wikitable"
| Order number of the tumor
| Order number of the tumour
|-
|-
| RHC registration number of the tumor
| RHC registration number of the tumour
|-
|-
| Date of registration of the tumor
| Date of registration of the tumour
|-
|-
| Date of tumor diagnosis
| Date of tumour diagnosis
|-
|-
| Basis of diagnosis
| Basis of diagnosis
Line 56: Line 58:
| Laterality
| Laterality
|-
|-
| Multifocal tumor
| Multifocal tumour
|-
|-
| Country of residence at the time of diagnosis
| Country of residence at the time of diagnosis
Line 64: Line 66:
| Locality of residence at the time of diagnosis
| Locality of residence at the time of diagnosis
|-
|-
| Circumstances of tumor discovery
| Circumstances of tumour discovery
|-
|-
| Family history
| Family history
Line 90: Line 92:
| Tests results (staging evaluation)
| Tests results (staging evaluation)
|-
|-
| Tests date of serum tumor markers
| Tests date of serum tumour markers
|-
|-
| Result of serum tumor markers
| Result of serum tumour markers
|-
|-
| Laboratory of serum tumor markers
| Laboratory of serum tumour markers
|-
|-
| Clinical tumor size
| Clinical tumour size
|-
|-
| Clinical lymph node involvement
| Clinical lymph node involvement
Line 105: Line 107:
|}
|}


'''Table 4''': Histological characteristics of the tumor.
'''Table 4''': Histological characteristics of the tumour.
{| class="wikitable"
{| class="wikitable"
| Cytology procedure
| Cytology procedure
Line 133: Line 135:
| Capsular rupture
| Capsular rupture
|-
|-
| Percentage of tumor invasion
| Percentage of tumour invasion
|-
|-
| Distance from resection margins
| Distance from resection margins
Line 139: Line 141:
| Specific scores by location
| Specific scores by location
|-
|-
| Conducted analises of tissue tumor markers and molecular alterations
| Conducted analises of tissue tumour markers and molecular alterations
|-
|-
| Date of analises of tissue tumor markers and molecular alterations
| Date of analises of tissue tumour markers and molecular alterations
|-
|-
| Result of analises of tissue tumor markers and molecular alterations
| Result of analises of tissue tumour markers and molecular alterations
|-
|-
| Laboratory of analises of tissue tumor markers and molecular alterations
| Laboratory of analises of tissue tumour markers and molecular alterations
|-
|-
| Histological size
| Histological size
Line 153: Line 155:
| Number of examined and positive lymph nodes
| Number of examined and positive lymph nodes
|-
|-
| Tumor residue
| Tumour residue
|-
|-
| Pathological TNM,
| Pathological TNM,
Line 166: Line 168:
|}
|}


'''Table 5''': Revised diagnosis of the tumor.
'''Table 5''': Revised diagnosis of the tumour.
{| class="wikitable"
{| class="wikitable"
| Revised incidence date  
| Revised incidence date  
Line 256: Line 258:
|}
|}


'''Table 7''': Tumor follow-up.
'''Table 7''': Tumour follow-up.
{| class="wikitable"
{| class="wikitable"
| Location
| Location
Line 448: Line 450:
'''Table 1''': Examinations reports sent by the laboratories to RNC.
'''Table 1''': Examinations reports sent by the laboratories to RNC.
{| class="wikitable"
{| class="wikitable"
| Analysis of Tumor Markers
| Analysis of Tumour Markers
|-
|-
| Analysis of Serum Tumor Markers
| Analysis of Serum Tumour Markers
|-
|-
| Analysis of Tissue Tumor Markers
| Analysis of Tissue Tumour Markers
|-
|-
| Analysis of Molecular Alterations with Predictive Value for Response to Chemotherapy or Targeted Therapy
| Analysis of Molecular Alterations with Predictive Value for Response to Chemotherapy or Targeted Therapy
|-
|-
| Cytology performed in cases of severe dysplasia and malignant tumors
| Cytology performed in cases of severe dysplasia and malignant tumours
|}
|}

Latest revision as of 14:56, 4 December 2025

forresearchers luxembourgcountry Go back to Database: National Register of Cancer (RNC) (Luxembourg) page

Source: Click here to learn more

Information provided by hospital cancer registries (RHC)[edit | edit source]

Table 1: Patient identification.

National pseudo-anonymization RNC number of the patient
Date of birth
Gender
Country of birth
Hospital file number
RHC registration number
Country of the patient
Postal code of the patient
Municipality of the patient
Referring primary care physician

Table 2: Patient status.

Vital status
Date of last contact
Date of death
Cause of death
Autopsy

Table 3: Clinical description of the disease and staging.

Order number of the tumour
RHC registration number of the tumour
Date of registration of the tumour
Date of tumour diagnosis
Basis of diagnosis
ICD code (topography and morphology)
Laterality
Multifocal tumour
Country of residence at the time of diagnosis
Postal code of residence at the time of diagnosis
Locality of residence at the time of diagnosis
Circumstances of tumour discovery
Family history
Personal history
Comorbidities
Performance score (WHO/ECOG)
Risk factors
Results of clinical examination (Initial assessment)
Types of performed tests (Initial assessment)
Tests dates (Initial assessment)
Tests results (Initial assessment)
Types of performed tests (staging evaluation)
Tests dates (staging evaluation)
Tests results (staging evaluation)
Tests date of serum tumour markers
Result of serum tumour markers
Laboratory of serum tumour markers
Clinical tumour size
Clinical lymph node involvement
Clinical TNM
Clinical metastases at the time of diagnosis

Table 4: Histological characteristics of the tumour.

Cytology procedure
Date of cytology procedure
Result of cytology procedure
Laboratory of cytology procedure
Biopsy procedure
Date of biopsy procedure
Result of biopsy procedure
Laboratory of biopsy procedure
Vascular invasion
Lymphatic invasion
Perineural sheath invasion
Vascular emboli
Capsular rupture
Percentage of tumour invasion
Distance from resection margins
Specific scores by location
Conducted analises of tissue tumour markers and molecular alterations
Date of analises of tissue tumour markers and molecular alterations
Result of analises of tissue tumour markers and molecular alterations
Laboratory of analises of tissue tumour markers and molecular alterations
Histological size
Pathological lymph node involvement
Number of examined and positive lymph nodes
Tumour residue
Pathological TNM,
Specific grade by location
Laboratory
Pathological Metastases at the time of diagnosis
Grouping by extension stages.

Table 5: Revised diagnosis of the tumour.

Revised incidence date
Revised basis of diagnosis
Revised ICD code (topography and morphology)
Laterality
Laboratory

Table 6: Information on therapeutic management.

Initial treatment performed
Inclusion in a therapeutic trial
Type of surgical intervention
Date of surgical intervention
Post-operative complications
Procedure for excision of regional lymph nodes
Surgeon's RNC identification number
Hospital facility
Date of discharge from hospital
Type of chemotherapy and drug molecules
Chemotherapy start date
Chemotherapy referring physician
Chemotherapy hospital facility.
Type of hormone therapy and drug molecules
Hormone terapy start date
Hormone terapy referring physician
Hormone therapy hospital facility
Type of radiotherapy
Radiotherapy irradiated fields
Radiotherapy start date
Radiotherapy total dose
Radiotherapy number of sessions
Radiotherapy referring physician
Radiotherapy center
Type of targeted therapy and drug molecules
Targeted Therapy start date
Targeted Therapy referring physician
Targeted Therapy hospital facility
Other Treatments
Date of genetic consultation
Location of genetic consultation.
Date of Multidisciplinary Consultation Meetings (RCP)
Location of RCP
Title of the RCP
RNC identification number of RCP attending physicians
Nature of RCP proposal
Proposed therapeutic protocol

Table 7: Tumour follow-up.

Location
Date of first recurrence
Basis of diagnosis
Location of first distant metastasis
Date of first distant metastasis

Information provided by the National Breast Cancer Screening Program[edit | edit source]

Table 1: National RNC pseudo-anonymization number of the woman.

Date of birth)
Country
Postal code
Locality (town/city)
Dates of Invitations to the Mammography Program
Dates of Participation in the Mammography Program
Dates of examinations conducted as part of the Mammography Program
Types of examinations conducted as part of the Mammography Program
Results of examinations conducted as part of the Mammography Program

Information provided by the National Health Fund (CNS)[edit | edit source]

Table 1: Data to be transmitted to RNC per patient (Databases of patients treated abroad).

National RNC Pseudo-anonymization Number of the patient
Date of birth
Gender
Country
Postal code
Locality (town/city)
Name and specialty of the physician who requested services abroad
Data on the pathology
Types of services
Dates of services
Locations of services

Table 2: Data to be transmitted to RNC per hospital stay for cancer.

National RNC Pseudo-anonymization Number of the patient
Date of birth
Gender
Country
Postal code
Locality (town/city)
ICD-10 Codes for the discharge diagnosis
Name of the hospital facility related to the considered hospital stay
Admission date
Discharge date
Mode of hospital discharge.

Information provided by the Joint European Communities Health Insurance Scheme (RCAM)[edit | edit source]

Table 1: Data to be transmitted to RNC per patient.

National RNC Pseudo-anonymization Number of the patient
Date of birth
Gender
Country
Postal code
Locality (town/city)
Name and specialty of the physician who requested services abroad
Data on the pathology
Types of services
Dates of services
Locations of services

Table 2: Data to be transmitted to RNC per hospital stay for cancer.

National RNC Pseudo-anonymization Number of the patient
Date of birth
Gender
Country
Postal code
Locality (town/city)
ICD-10 Codes for the discharge diagnosis
Name of the hospital facility related to the considered hospital stay
Admission date
Discharge date
Mode of hospital discharge

Information provided by the Directorate of Health (death certificates)[edit | edit source]

Table 1: Data to be transmitted to RNC per deceased individual.

National RNC Pseudo-anonymization Number of the patient
Date of birth
Gender
Country (at the time of death)
Postal code (at the time of death)
Locality (at the time of death)
Date of death
Place of death
Primary cause of death (1 ICD-10 code)
Immediate diseases (up to 3 possible ICD-10 codes)
Concurrent diseases (up to 2 possible ICD-10 codes).

Information provided by the Civil status register[edit | edit source]

Table 1: Data to be transmitted to RNC per deceased individual.

National RNC Pseudo-anonymization Number of the patient
Date of birth
Gender
Country (at the time of death)
Postal code (at the time of death)
Locality (at the time of death)
Date of death
Place of death

Information provided by the private medical analysis laboratories[edit | edit source]

Table 1: Examinations reports sent by the laboratories to RNC.

Analysis of Tumour Markers
Analysis of Serum Tumour Markers
Analysis of Tissue Tumour Markers
Analysis of Molecular Alterations with Predictive Value for Response to Chemotherapy or Targeted Therapy
Cytology performed in cases of severe dysplasia and malignant tumours